Infliximab Therapy in Very Early Onset Crohn's Disease: Real-World Experience in China.

Youyou LuoQi ChengYouhong FangJindan YuJingan LouJie Chen

Published in: Digestive diseases and sciences (2020)

Very early onset Crohn's disease patients had similar non-response rates and mucosal healing rates as those who were 6 years or older during induction therapy. Greater discontinuation of infliximab due to adverse events was observed in very early onset Crohn's disease patients.

Keyphrases

early onset
late onset
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
stem cells
patient reported outcomes
mesenchymal stem cells
bone marrow
cell therapy